Clinical trials: Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis, ALS
A Study of Protein Metabolism, Microbiome and Investigational Probiotic Use in Patients With ALS
ALS, also known as "Lou Gehrig's" disease, is a neurodegenerative disease which is fatal. Treatment for ALS is limited and currently consists of primary symptom relief or support.
- Trial name
- NCT03324399
- Testing
- probiotic
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Avera McKennan Hospital & University Health Center
Amyotrophic Lateral Sclerosis
Investigation of Cannabinoid 2-receptor Expression in the Brain and Spine of ALS-patients Compared to Healthy Controls With PET (18F-RoSMALS)
This clinical trial is a phase 1 study in which investigations with the weakly radioactive substance [18F]-RoSMA-18-d6 are being carried out for the first time.
- Trial name
- 18F-RoSMALS (NCT05880563)
- Testing
- [18F]-RoSMA-18-d6
- Where
- Switzerland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Markus Weber
Amyotrophic Lateral Sclerosis, ALS
Phase II Study Using Thalidomide for the Treatment of ALS
The use of Thalidomide in patients with ALS who have disease progression.
- Trial name
- NCT00140452
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Amyotrophic Lateral Sclerosis
Nocturnal PtcCO2 Monitoring in Patients With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting motoneurons, with a prevalence around 5/100.000. Respiratory muscle involvement is a major feature in ALS and remains the main prognostic factor.
- Trial name
- NCT00879593
- Testing
- PtcCO2
- Where
- 2 sites in France
- Volunteers
- 66 people
- Sponsor
- Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche
Amyotrophic Lateral Sclerosis (ALS)
Influence of Olfacto-gustatory Sensoriality on the Nutritional Status of Patients With Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterised by progressive diffuse muscular paralysis due to the inexorable loss of motor neurons in the primary motor cortex, the corticospinal tract, the…
- Trial name
- GOUSLA (NCT06608004)
- Testing
- test taking
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Amyotrophic Lateral Sclerosis (ALS)
Determining the Safety of L-serine in ALS
The purpose of this study is to determine the safety of L-Serine in subjects with Amyotrophic Lateral Sclerosis (ALS) at varied doses.
- Trial name
- NCT01835782
- Testing
- L-Serine
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Phoenix Neurological Associates, LTD
Amyotrophic Lateral Sclerosis
Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS).
This is a phase 2a open label, multicentre design study to investigate the safety of Triumeq in patients with ALS at 24 weeks post treatment.
- Trial name
- Lighthouse (NCT02868580)
- Testing
- Triumeq
- Where
- 4 sites in Australia
- Volunteers
- 43 people
- Sponsor
- Neuroscience Trials Australia
Amyotrophic Lateral Sclerosis
Epidemiology and Genetics of the Amyotrophic Lateral Sclerosis in the French West Indies
The diagnosis and the follow-up of the patients reached of SLA is centralized, since a few years, at the the Caribbean Reference center of the rare neurological diseases (CERCA labélisé in 2006) in Martinique and at the Unity of…
- Trial name
- SLA-DOM (NCT03367650)
- Testing
- Blood sample and environmental survey
- Where
- 2 sites in Guadeloupe, Martinique
- Volunteers
- 70 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Amyotrophic Lateral Sclerosis
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
PIONEER-ALS is a Phase 1/2, multicenter, open-label, ascending dose, uncontrolled, first-in-human study that will evaluate the safety, tolerability and effects on clinical and biomarker endpoints of intracisternal administration…
- Trial name
- ALS (NCT07287397)
- Testing
- VTx-002, Preventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone
- Where
- 11 sites in United States, Belgium and 2 more
- Volunteers
- 36 people
- Sponsor
- Vector Y Therapeutics
COPD, Severe Early-Onset, Ventilatory Failure
Customized Masks in Non-Invasive Mechanical Ventilation
In non-invasive mechanical ventilation (NIMV), the interface is the primary determinant of success, as adherence and quality of therapy mainly depend on it.
- Conditions
- COPD, Severe Early-Onset, Ventilatory Failure, Als, Non Invasive Ventilation
- Trial name
- NCT06215391
- Testing
- 3d printed mask
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Hospital Universitario 12 de Octubre
Amyotrophic Lateral Sclerosis
Randomized, Double-blind, Safety and Efficacy of Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis
Erythropoietin is neuroprotective in animal models of neurodegenerative diseases including amyotrophic lateral sclerosis (ALS). The aim of this study was to determine the safety and feasibility of repetitive high-dose recombinant…
- Trial name
- NCT03835507
- Testing
- recombinant human erythropoietin(rhEPO)
- Where
- South Korea
- Volunteers
- 64 people
- Sponsor
- Hanyang University Seoul Hospital
Tetraplegia/Tetraparesis, Quadriplegia
GB-PRIME: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices
The GB-PRIME Study is an early feasibility study designed to assess the clinical safety and functionality of the Neuralink N1 Implant and R1 Robot.
- Conditions
- Tetraplegia/Tetraparesis, Quadriplegia, Quadriplegia/Tetraplegia, Cervical Spinal Cord Injury
- Trial name
- GB-PRIME (NCT07127172)
- Testing
- N1 Implant, R1 Robot
- Where
- 2 sites in United Kingdom
- Volunteers
- 7 people
- Sponsor
- Neuralink Corp
Sporadic Amyotrophic Lateral Sclerosis
Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis
INTRODUCTION: Amyotrophic Lateral Sclerosis (ALS) is a degenerative disease of the motor neurones of the brain and the spinal cord. The pathophysiological mechanisms of the disease remain unknown.
- Trial name
- Fibro-ALS (NCT02969759)
- Testing
- Skin Biopsy
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Angers
Amyotrophic Lateral Sclerosis
The National Amyotrophic Lateral Sclerosis Registry
The purpose of this registry is to (A) better describe the incidence and prevalence of Amyotrophic Lateral Sclerosis (ALS) in the United States;(B) examine appropriate factors, such as environmental and occupational, that may be…
- Trial name
- NCT01772602
- Where
- United States
- Volunteers
- 30,000 people
- Sponsor
- Centers for Disease Control and Prevention
Amyotrophic Lateral Sclerosis
Efficacy and Safety of Cyclophosphamide in Amyotrophic Lateral Sclerosis
The goal of this clinical trial is to learn whether cyclophosphamide (CTX) combined with standard treatment can slow disease progression in adults with amyotrophic lateral sclerosis (ALS).
- Trial name
- CORTEX-ALS (NCT07834450)
- Testing
- Cyclophosphamide, Riluzole
- Volunteers
- 60 people
- Sponsor
- Huashan Hospital
Neuromuscular Diseases
Muscle Oxygenation in Effort in Neuromuscular Diseases
Previous studies showed modifications of muscle oxygenation parameters in muscular dystrophies du to an impairment or an absence of dystrophin.
- Trial name
- OXYNEMU (NCT02789059)
- Testing
- muscle oxygenation
- Where
- 3 sites in France
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Amyotrophic Lateral Sclerosis
A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation
The ALSpire Study is a clinical trial evaluating the investigational drug BIIB105 in adults living with amyotrophic lateral sclerosis (ALS). The ALSpire Study consists of two parts: Part 1: 6-month placebo-controlled study.
- Trial name
- ALSpire (NCT04494256)
- Testing
- BIIB105
- Where
- 17 sites in United States, Canada and 2 more
- Volunteers
- 99 people
- Sponsor
- Biogen
Amyotrophic Lateral Sclerosis
DESIPHER_Speech Degradation as an Indicator of Physiological Degeneration in ALS
A disease called Amyotrophic lateral sclerosis (or ALS), which leads to difficulty swallowing, breathing, and movement, has been found to be higher for those serving in the military than in the general population.
- Trial name
- NCT02675075
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- VA Office of Research and Development
ALS
Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral Sclerosis
The primary objective of this study is to assess the safety and tolerability, with emphasis on the oral cavity, of ROSF (containing riluzole 50mg) in subjects with amyotrophic lateral sclerosis (ALS) administered twice daily for…
- Trial name
- NCT03457753
- Testing
- Riluzole Oral Soluble Film
- Where
- United States
- Sponsor
- Aquestive Therapeutics
Amyotrophic Lateral Sclerosis, ALS
A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of PLL001 in ALS Patients
FIH, Phase 1/2, multi-centre, randomised, double-blind, placebo controlled study with an optional open-label dosing extension to assess the safety, tolerability, efficacy, and Pharmacodynamics (PD) of single or multiple (up to 48…
- Trial name
- NCT06513546
- Volunteers
- 153 people
- Sponsor
- PLL TX AUSTRALIA PTY LTD